Enter Revive Therapeutics, a biotech company with its fingers in several pies: the emerging psychedelics industry, where it has a research partnership with the University of Wisconsin-Madison for formulation development and a clinical trial for substance use using psilocybin; the cannabis industry, where it has patented several unique cannabinoid delivery methods; and more recently, the market for coronavirus treatments, where it is one of fewer than 20 companies undertaking a phase 3 FDA trial—and the one with the lowest market cap.
University Communications